Evolutionary divergence of polymorphic HLA residues predicts clinical outcomes after haploidentical stem cell transplantation in patients with AML
Shukaib Arslan, Kevin Quann(University of Pittsburgh), Geoffrey Shouse(City Of Hope National Medical Center), Anthony S. Stein(University of Hohenheim), Sawa Ito(National Institutes of Health), Kathleen Dorritie(University of Pittsburgh), Guido Marcucci(City Of Hope National Medical Center), Monzr M. Al Malki(City of Hope), Alison R. Sehgal(UPMC Hillman Cancer Center), Padma Sri Katikaneni(UPMC Hillman Cancer Center), Emily Geramita(University of Pittsburgh Medical Center), Haris Ali(City of Hope), Warren D. Shlomchik(University of Pittsburgh), Annie Im(UPMC Hillman Cancer Center), Ryotaro Nakamura(City Of Hope National Medical Center), Nicole Karras(City Of Hope National Medical Center), Ketevan Gendzekhadze(City Of Hope National Medical Center), Joseph Franz(UPMC Hillman Cancer Center), James M. Rossetti(UPMC Hillman Cancer Center), K M Cooper(UPMC Hillman Cancer Center), Jing‐Zhou Hou(Center for Cancer and Blood Disorders)
Cited by 0
Related Papers
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
|New England Journal of Medicine|2006|1.3k
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2014|1.3k
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782